Close Menu

NEW YORK – T2 Biosystems is anticipating about a 40 percent jump in second quarter 2020 revenues, the firm said on Tuesday. It has also completed validating and launched a molecular diagnostic test for SARS-CoV-2.

Lexington, Massachusetts-based T2 estimates total Q2 revenues to be in the range of $2.4 million to $2.6 million, compared to revenues of $1.8 million in the prior-year period.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.


As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Sponsored by

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.